132606-40-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-6-chloro-2-methylpyridine is utilized as an intermediate in the synthesis of pharmaceuticals, playing a crucial role in the development of new drugs. Its unique structure allows for the creation of diverse medicinal compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-6-chloro-2-methylpyridine serves as an intermediate for the synthesis of various agrochemicals, including pesticides and herbicides. Its chemical properties enable the production of effective compounds for crop protection and management.
Used as a Building Block for Organic Synthesis:
3-Bromo-6-chloro-2-methylpyridine is recognized for its versatility as a building block in the preparation of functionalized pyridine derivatives. Its reactivity and structural features make it a valuable component in the synthesis of complex organic molecules for various applications, including materials science and specialty chemicals.
It is essential to handle 3-Bromo-6-chloro-2-methylpyridine with care and appropriate safety measures due to its potential hazards when mishandled.

InChI:InChI=1/C6H5BrClN/c1-4-5(7)2-3-6(8)9-4/h2-3H,1H3

Upstream product

• 164666-68-6 3-amino-6-chloro-2-methylpyridine 
• 42753-71-9 5-bromo-6-methyl-pyridin-2-ylamine 
• 22280-60-0 6-chloro-4-methyl-3-nitropyridine 
• 126717-59-7 3-bromo-6-methoxy-2-methylpyridine 

Downstream Products

• 944317-25-3 (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[(3-bromo-6-chloropyridin-2-yl)methyl]-4-methyl-1,3-oxazolidin-2-one 
• 1270038-10-2 (4S,5R)-5-[3-5-bis(trifluoromethyl)phenyl]-3-[(3-bromo-6-methoxypyridin-2-yl)methyl]-4-methyl-1,3-oxazolidin-2-one 
• 1270038-11-3 methyl 3-(3-[2-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)-6-methoxypyridin-3-yl]-4-methoxyphenyl)propanoate 
• 1270038-08-8 3-{3-[2-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)-6-methoxypyridin-3-yl]-4-methoxyphenyl}propanoic acid 
• 1093879-95-8 (6-chloro-2-methylpyridin-3-yl)methanol 
• 249291-79-0 6-chloro-3-iodo-2-methylpyridine 
• 1427324-31-9 8-bromo-5-chloroimidazo[1,5-a]pyridine 
• 1374131-28-8 3-{3-[6-azetidin-1-yl-2-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)pyridin-3-yl]-4-methoxyphenyl}propanoic acid 
• 1374131-12-0 methyl 5-{3-[6-azetidin-1-yl-2-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)pyridin-3-yl]-4-methoxyphenyl}-2-furoate 
• 1374131-11-9 methyl 5-{3-[6-azetidin-1-yl-2-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)pyridin-3-yl]-4-methoxyphenyl}-4-methylthiophene-2-carboxylate 
• 1374130-71-8 methyl 3-{3-[6-azetidin-1-yl-2-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)pyridin-3-yl]-4-methoxyphenyl}propanoate 
• 1374134-57-2 (4S,5R)-3-({6-azetidin-1-yl-3-[5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-2-methoxyphenyl]pyridin-2-yl}methyl)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one 
• 1374134-55-0 (4S,5R)-3-{[6-azetidin-1-yl-3-(5-iodo-2-methoxyphenyl)pyridin-2-yl]methyl}-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one 
• 1374134-56-1 (4S,5R)-3-{[3-(5-amino-2-methoxyphenyl)-6-azetidin-1-ylpyridin-2-yl]methyl}-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one 

Relevant academic research and scientific papers

CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR

CCompounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substitiuted phenyl group or indanyl group.Formula (I)

PYRIDYL OXAZOLIDINONE CETP INHIBITOR

The compound of Formula I, including pharmaceutically acceptable salts, is a CETP inhibitor, and is useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula 1, R is H or Csub

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

CETP INHIBITORS

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3

Fused heterotricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.

Stereoselective synthesis of conformationally constrained tropane analogues: 6-Chloro-2,5-diazatetracyclo[8.5.0.02,13.0 4,9]pentadeca-4,6,8-triene-11-one and 6-chloro-2,7-diazatetracyclo- [8.5.0.02,13.04,9]pentadeca-4,6,8-triene-11-one

Two conformationally constrained tropane derivatives were prepared as rigid nicotinic acetylcholine receptor ligands. A palladium catalyzed intramolecular α-arylation reaction was employed to generate the tricyclic compounds in good yields from N-(bromo-chloropyridylmethyl)-8-azabicyclo[3.2.1]octan-3-ones.

P38 MAP kinase inhibitors. part 1: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold

A new class of p38 antagonists based on 3,4-dihydropyrido[3,2,-d]pyrimidine scaffold has been developed. These inhibitors exhibit unprecedented selectivity towards p38 over other very closely related kinases. Compounds 25, 33, and 34 were identified as be

Synthesis of dihalopicoline N-oxides and their 4-nitro derivatives

Three aminohalo-substituted α- and β-picolines, six dihalo-substituted α- and β-picolines, six dihalo-substituted α- and β-picoline N-oxides and six respective dihalo-4-nitropicoline N-oxides were synthesized in excellent yields. Some properties of the products were reported. 1997 Plenum Publishing Corporation.

A Convenient Synthesis of Halogenated 2-Chloropyridines by Transformation of Halogenated 2-Methoxypyridines under Vilsmeier-Haack Conditions

Several halogenated 2-chloropyridines 2a-2h were conveniently synthesized by transformation of halogenated 2-methoxypyridines 1a-1h under Vilsmeier-Haack conditions in a yield of 50-71percent.